# Long-Term Study of IGIV, 10% in Alzheimer´s Disease

> **NCT01736579** · PHASE3 · TERMINATED · sponsor: **Baxalta now part of Shire** · enrollment: 6 (actual)

## Conditions studied

- Alzheimer´s Disease

## Interventions

- **DRUG:** Immune Globulin Intravenous (Human), 10% (IGIV, 10%)

## Key facts

- **NCT ID:** NCT01736579
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-11-29
- **Primary completion:** 2013-06-04
- **Final completion:** 2013-06-04
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** The study was terminated because the first Phase 3 did not demonstrate efficacy on the co-primary endpoints. The known safety profile remained unchanged.
- **Last updated:** 2021-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01736579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01736579, "Long-Term Study of IGIV, 10% in Alzheimer´s Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01736579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*